# IPEV Fair Value Methods Implementation Status

## ✅ Currently Implemented Methods

### 1. **Market Approach**
- ✅ **Comparables Method** (`_calculate_comparables`)
  - Revenue multiples
  - Growth-adjusted multiples
  - Industry-specific multiples
  - DLOM (Discount for Lack of Marketability) adjustments

### 2. **Income Approach**
- ✅ **DCF (Discounted Cash Flow)** (`_calculate_dcf`)
  - 5-year projection model
  - Terminal value calculation
  - WACC-based discounting
  - Growth rate assumptions

### 3. **Probability-Weighted Methods**
- ✅ **PWERM (Probability-Weighted Expected Return Method)** (`_calculate_pwerm`)
  - Multiple exit scenarios (IPO, M&A, liquidation)
  - Stage-specific probabilities
  - Time-weighted present values
  - Scenario modeling (bear/base/bull)

### 4. **Option-Based Methods**
- ✅ **OPM (Option Pricing Model)** (`_calculate_opm`)
  - Black-Scholes implementation
  - Volatility calculations
  - Exercise price modeling

### 5. **Asset-Based Methods**
- ✅ **Waterfall Analysis** (`_calculate_waterfall`)
  - Liquidation preferences
  - Participation rights
  - Common vs preferred stock values
  - Exit distribution modeling

## ✅ Recently Added IPEV Methods (2024-09-20)

### 1. **Recent Transaction Method** 
- **Status**: ✅ IMPLEMENTED (`_calculate_recent_transaction`)
- **Features**:
  - Time-based adjustments (<3mo, 3-6mo, 6-12mo, 12-18mo, >18mo)
  - Performance adjustments based on growth rate
  - Market condition adjustments
  - Stage progression adjustments
  - DLOM application (15% standard)
  - Confidence scoring based on recency

### 2. **Cost Method**
- **Status**: ✅ IMPLEMENTED (`_calculate_cost_method`)
- **Features**:
  - Recent investment valuation (<12 months)
  - Impairment indicators (negative/slow growth)
  - Enhancement indicators (strong performance)
  - Confidence based on investment recency

### 3. **Milestone/Calibration Method**
- **Status**: ✅ IMPLEMENTED (`_calculate_milestone`)
- **Features**:
  - Revenue milestones ($100K, $1M, $10M, $50M, $100M+)
  - Industry-specific milestones:
    - Biotech: Clinical trial phases
    - Hardware: Prototype/production milestones
    - AI/ML: Customer acquisition milestones
  - Stage progression multipliers
  - Risk adjustments

### 4. **Net Assets Method**
- **Status**: NOT IMPLEMENTED
- **Required for**: Asset-heavy businesses, holding companies
- **IPEV Requirement**: Book value adjustments for fair value

### 5. **Industry-Specific Methods**
- **Status**: PARTIALLY IMPLEMENTED
- **Missing**: SaaS-specific metrics (ARR multiples, Rule of 40)
- **Missing**: Biotech risk-adjusted NPV
- **Missing**: Real estate cap rates

## 🔧 Recommended Implementation Priority

1. **Recent Transaction Method** (CRITICAL)
   - Most commonly used for VC valuations
   - Required for ASC 820/IFRS 13 compliance
   - Relatively simple to implement

2. **Cost Method** (HIGH)
   - Needed for seed/pre-seed valuations
   - Simple implementation
   - Often used as fallback

3. **Milestone Method** (MEDIUM)
   - Important for deep tech/biotech
   - More complex implementation
   - Requires milestone tracking

4. **Industry-Specific Enhancements** (MEDIUM)
   - ARR multiples for SaaS
   - GMV multiples for marketplaces
   - AUM multiples for fintech

5. **Net Assets Method** (LOW)
   - Rarely used for tech companies
   - More relevant for traditional businesses

## 📊 IPEV Compliance Score: 60%

We have the core methods but missing the most commonly used "Recent Transaction" method which is critical for fair value reporting.